NCT07589634
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07589634
Title A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma (TRI Pro)
Acronym TRI Pro
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Janssen Research & Development, LLC
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.